CN107137661A - 一种治疗疣状胃炎的中药组合物 - Google Patents
一种治疗疣状胃炎的中药组合物 Download PDFInfo
- Publication number
- CN107137661A CN107137661A CN201710335450.XA CN201710335450A CN107137661A CN 107137661 A CN107137661 A CN 107137661A CN 201710335450 A CN201710335450 A CN 201710335450A CN 107137661 A CN107137661 A CN 107137661A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- treatment
- medicine composition
- decoction
- decocted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 208000007882 Gastritis Diseases 0.000 title claims abstract description 23
- 241001661641 Verrucosa Species 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 13
- 241001313857 Bletilla striata Species 0.000 claims abstract description 7
- 241000219357 Cactaceae Species 0.000 claims abstract description 7
- 235000008671 Calycanthus floridus Nutrition 0.000 claims abstract description 7
- 235000008670 Calycanthus occidentalis Nutrition 0.000 claims abstract description 7
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 7
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 7
- 244000148992 Lindera benzoin Species 0.000 claims abstract description 7
- 235000004520 Lindera benzoin Nutrition 0.000 claims abstract description 7
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 claims abstract description 7
- 244000138993 panchioli Species 0.000 claims abstract description 7
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 6
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 6
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 6
- 239000004576 sand Substances 0.000 claims abstract description 6
- 235000013976 turmeric Nutrition 0.000 claims abstract description 6
- 235000021419 vinegar Nutrition 0.000 claims abstract description 6
- 239000000052 vinegar Substances 0.000 claims abstract description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 4
- 239000002023 wood Substances 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 12
- 229920001983 poloxamer Polymers 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 9
- 108010064470 polyaspartate Proteins 0.000 claims description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 229960000502 poloxamer Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000009413 insulation Methods 0.000 claims description 6
- 239000003595 mist Substances 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 244000275012 Sesbania cannabina Species 0.000 claims description 3
- 239000010495 camellia oil Substances 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229940080237 sodium caseinate Drugs 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000008279 sol Substances 0.000 description 5
- 241000237502 Ostreidae Species 0.000 description 3
- 241000233948 Typha Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000023652 chronic gastritis Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000020636 oyster Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 240000001398 Typha domingensis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗疣状胃炎的中药组合物，涉及中药组合物技术领域，由如下重量的中药制成：鲜仙人掌30‑50g、破故纸3‑9g、炙鳖甲9‑30g、煅牡蛎15‑30g、白芨粉6‑9g、降香3‑10g、姜黄3‑10g、乌药8‑12g、煅瓦楞子9‑15g、桂枝7‑9g、生蒲黄6‑12g。利用本发明所述中药组合物经常规煎煮制得的药液用于治疗疣状胃炎，每天服用两次，4周为一个疗程，临床应用10余年，服用2个疗程后治愈率达到88％、显效率达到92％、有效率达到96％。
Description
技术领域：
本发明涉及中药组合物技术领域，具体涉及一种治疗疣状胃炎的中药组合物。
背景技术：
疣状胃炎，是一种上腹有烧灼感、泛酸、暖气或疼痛，病情反复发作的一种疾病。特征是胃黏膜有多个疣状、彭大或丘疹样隆起，顶端可见黏膜缺损或脐样凹陷，中央有糜烂的一种疾病类型。虽然形态学和组织学上有独特改变，但临床表现和普通型慢性胃炎无区别，治疗多为对症治疗，药物包括制酸剂、H2拮抗剂和质子泵抑制剂，同时应避免服用可使症状加重的药物和食物，复发和恶化多见。目前，采用西药治疗疣状胃炎存在起效慢、副作用大、依赖性强等缺陷。
发明内容：
本发明所要解决的技术问题在于提供一种治疗效果好、服药时间短且治愈后不易复发的治疗疣状胃炎的中药组合物。
本发明所要解决的技术问题采用以下的技术方案来实现：
一种治疗疣状胃炎的中药组合物，由如下重量的中药制成：
鲜仙人掌30-50g、破故纸3-9g、炙鳖甲9-30g、煅牡蛎15-30g、白芨粉6-9g、降香3-10g、姜黄3-10g、乌药8-12g、煅瓦楞子9-15g、桂枝7-9g、生蒲黄6-12g。
所述治疗疣状胃炎的中药组合物的煎服方法：将上述中药置于砂锅内，并加水没过药面，浸泡60-90min，再用文火煎煮，煮沸后续煮15-20min，静置，溶液过滤即得药液；每剂煎两次，每次煎煮药液200mL。
所述治疗乳腺增生的中药组合物的煎服方法：将上述中药和占中药总重0.5％的促提剂置于砂锅内，并加水没过药面，浸泡60-90min，再用文火煎煮，煮沸后续煮15-20min，静置，溶液过滤即得药液；每剂煎两次，每次煎煮药液200mL。
所述促提剂由如下重量的原料混合而成：壳寡糖/聚天门冬氨酸3g、泊洛沙姆/交联羧甲基纤维素钠1g、预糊化淀粉0.3g、羟丙甲纤维素邻苯二甲酸酯0.1g、甘草酸二钾0.1g、酪朊酸钠0.05g。
所述壳寡糖/聚天门冬氨酸的制备方法为：向15g水中加入2g聚天门冬氨酸和0.05g田菁胶，搅拌溶解完全后于微波频率2450MHz、输出功率700W下微波处理3min，再加入2g壳寡糖和0.05g茶油，搅拌溶解完全后继续微波处理5min，并转入0～5℃环境中静置30min，随后再次微波处理5min，所得混合液自然冷却至室温，最后送入喷雾干燥机中，干燥所得颗粒经超微粉碎机制成微粉，即得壳寡糖/聚天门冬氨酸。
所述泊洛沙姆/交联羧甲基纤维素钠的制备方法为：将1g交联羧甲基纤维素钠和0.05g甘露醇升温至110～115℃保温混合10min，再加入1g泊洛沙姆和0.05g柠檬酸钠，继续在110～115℃保温混合15min，所得混合物转入-5～0℃环境中密封静置1h，最后利用超微粉碎机制成微粉，即得泊洛沙姆/交联羧甲基纤维素钠。
上述所制促提剂能显著加快药材药效成分的浸出速度，增加所制药液中药效成分的有效含量，从而使所制药液具有起效快、治愈时间短的优势；并且该促提剂经静置后以沉淀形式沉降到药材表面，经过滤后仅有微量促提剂残留在药液中，残留在药液中的少量促提剂也不会对人体造成任何不良反应和毒副作用。
作用机理：
仙人掌理气和胃消胀，破故纸消疣温胃，鳖甲软坚滋阴，煅牡蛎、煅瓦楞子祛疣、散结制酸，白芨修复胃黏膜、愈糜烂，降香、乌药、片姜黄行气、消胀止痛，桂枝温通行气、促血运，乳香、蒲黄活血生机、止痛止血。
本发明的有益效果是：利用本发明所述中药组合物经常规煎煮制得的药液用于治疗疣状胃炎，每天服用两次，4周为一个疗程，临床应用10余年，服用2个疗程后治愈率达到88％、显效率达到92％、有效率达到96％；并且添加促提剂煎煮制得的药液服用后起效更快，从而更有效地利用了药材的药效成分；同时经该中药组合物治愈后的患者随访2年未见复发，同时患者服药期间没有出现任何身体不适症状，使用安全性高，副作用极小。
具体实施方式：
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解，下面结合具体实施例，进一步阐述本发明。
实施例1
将40g鲜仙人掌、8g破故纸、20g炙鳖甲、20g煅牡蛎、6g白芨粉、8g降香、5g姜黄、10g乌药、12g煅瓦楞子、8g桂枝、10g生蒲黄置于砂锅内，并加水没过药面，浸泡90min，再用文火煎煮，煮沸后续煮15min，静置，溶液过滤即得药液；每剂煎两次，每次煎煮药液200mL。
实施例2
将50g鲜仙人掌、5g破故纸、15g炙鳖甲、15g煅牡蛎、8g白芨粉、5g降香、8g姜黄、8g乌药、10g煅瓦楞子、8g桂枝、6g生蒲黄置于砂锅内，并加水没过药面，浸泡90min，再用文火煎煮，煮沸后续煮15min，静置，溶液过滤即得药液；每剂煎两次，每次煎煮药液200mL。
实施例3
将50g鲜仙人掌、5g破故纸、15g炙鳖甲、15g煅牡蛎、8g白芨粉、5g降香、8g姜黄、8g乌药、10g煅瓦楞子、8g桂枝、6g生蒲黄和占中药总重0.5％的促提剂置于砂锅内，并加水没过药面，浸泡90min，再用文火煎煮，煮沸后续煮15min，静置，溶液过滤即得药液；每剂煎两次，每次煎煮药液200mL。
促提剂的制备：由3g壳寡糖/聚天门冬氨酸、1g泊洛沙姆/交联羧甲基纤维素钠、0.3g预糊化淀粉、0.1g羟丙甲纤维素邻苯二甲酸酯、0.1g甘草酸二钾和0.05g酪朊酸钠混合而成。
壳寡糖/聚天门冬氨酸的制备：向15g水中加入2g聚天门冬氨酸和0.05g田菁胶，搅拌溶解完全后于微波频率2450MHz、输出功率700W下微波处理3min，再加入2g壳寡糖和0.05g茶油，搅拌溶解完全后继续微波处理5min，并转入0～5℃环境中静置30min，随后再次微波处理5min，所得混合液自然冷却至室温，最后送入喷雾干燥机中，干燥所得颗粒经超微粉碎机制成微粉，即得壳寡糖/聚天门冬氨酸。
泊洛沙姆/交联羧甲基纤维素钠的制备：将1g交联羧甲基纤维素钠和0.05g甘露醇升温至110～115℃保温混合10min，再加入1g泊洛沙姆和0.05g柠檬酸钠，继续在110～115℃保温混合15min，所得混合物转入-5～0℃环境中密封静置1h，最后利用超微粉碎机制成微粉，即得泊洛沙姆/交联羧甲基纤维素钠。
实施例4
(1)动物急性毒性试验
试验对象：小白鼠，体重18-22g，雌雄各半；
试验方法：取小白鼠130只，随机选取10只作为空白组，其余平均分为试验一组、试验二组、试验三组，每个试验组再平均分为4个小组，每个小组10只，试验组给药前禁食12h，将实施例1、实施例2和实施例3所制药液分别灌喂试验一组、试验二组、试验三组小白鼠，每只每次灌喂10ml，24h内分别灌喂1、2、3、4次，具体给药组别和给药时间见表1，灌喂后观察7天；
表1给药组别和给药时间表
试验结果：试验小白鼠活动正常，无毒性反应，无死亡。
(2)动物长期毒性试验
试验对象：大白鼠，体重120-150g，雌雄各半；
试验方法：取大白鼠80只，分成4组，每组20只，其中一组为空白组，其余为试验一组、试验二组、试验三组，将实施例1、实施例2和实施例3所制药液分别灌喂试验一组、试验二组、试验三组大白鼠，试验组每日分别灌喂两次，每天灌喂50ml，连续灌喂90天，监测体重，于最后一次给药后24h断头处死，测血、尿常规、肝功能、肾功能、取心、肾等内脏，观察组织形态的变化；
试验结果：试验组活动正常，无毒性反应，无死亡，处死后的各项检查与空白组无任何区别。
(3)临床研究
研究对象：设置促提剂分别不添加壳寡糖/聚天门冬氨酸、泊洛沙姆/交联羧甲基纤维素钠的对照例1和对照例2，随机选取250名疣状胃炎患者，平均分成5组，每组50人。
服用方法：每人每天服用两次，每次服用药液200mL，4周为一个疗程。
疗效测定：记录患者治疗情况，结果如表2所示。
表2疣状胃炎治疗情况
| 项目 | 实施例1 | 实施例2 | 实施例3 | 对照例1 | 对照例2 |
| 1个疗程治愈率 | 75％ | 75％ | 85％ | 80％ | 83％ |
| 1个疗程显效率 | 83％ | 84％ | 90％ | 88％ | 89％ |
| 1个疗程有效率 | 88％ | 89％ | 93％ | 90％ | 92％ |
| 2个疗程治愈率 | 87％ | 88％ | 90％ | 89％ | 90％ |
| 2个疗程显效率 | 92％ | 92％ | 94％ | 92％ | 93％ |
| 2个疗程有效率 | 96％ | 96％ | 97％ | 96％ | 96％ |
(4)典型病例
饶某，女，46岁，安徽长丰人，患慢性疣状胃炎5年，病情较重，服此方2个疗程后症状基本消失。
刘某，男，52岁，河南郑州人，患疣状胃炎3年，反复发作，服此方2个疗程后痊愈。
贺某，女，42岁，江苏南京人，患慢性疣状胃炎2年，服此方2个疗程后痊愈。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (6)
1.一种治疗疣状胃炎的中药组合物，其特征在于，由如下重量的中药制成：
鲜仙人掌30-50g、破故纸3-9g、炙鳖甲9-30g、煅牡蛎15-30g、白芨粉6-9g、降香3-10g、姜黄3-10g、乌药8-12g、煅瓦楞子9-15g、桂枝7-9g、生蒲黄6-12g。
2.根据权利要求1所述的治疗疣状胃炎的中药组合物，其特征在于，其煎服方法：将上述中药置于砂锅内，并加水没过药面，浸泡60-90min，再用文火煎煮，煮沸后续煮15-20min，静置，溶液过滤即得药液；每剂煎两次，每次煎煮药液200mL。
3.根据权利要求1所述的治疗疣状胃炎的中药组合物，其特征在于，其煎服方法：将上述中药和占中药总重0.5％的促提剂置于砂锅内，并加水没过药面，浸泡60-90min，再用文火煎煮，煮沸后续煮15-20min，静置，溶液过滤即得药液；每剂煎两次，每次煎煮药液200mL。
4.根据权利要求3所述的治疗疣状胃炎的中药组合物，其特征在于，所述促提剂由如下重量的原料混合而成：壳寡糖/聚天门冬氨酸3g、泊洛沙姆/交联羧甲基纤维素钠1g、预糊化淀粉0.3g、羟丙甲纤维素邻苯二甲酸酯0.1g、甘草酸二钾0.1g、酪朊酸钠0.05g。
5.根据权利要求4所述的治疗疣状胃炎的中药组合物，其特征在于，所述壳寡糖/聚天门冬氨酸的制备方法为：向15g水中加入2g聚天门冬氨酸和0.05g田菁胶，搅拌溶解完全后于微波频率2450MHz、输出功率700W下微波处理3min，再加入2g壳寡糖和0.05g茶油，搅拌溶解完全后继续微波处理5min，并转入0～5℃环境中静置30min，随后再次微波处理5min，所得混合液自然冷却至室温，最后送入喷雾干燥机中，干燥所得颗粒经超微粉碎机制成微粉，即得壳寡糖/聚天门冬氨酸。
6.根据权利要求4所述的治疗疣状胃炎的中药组合物，其特征在于，所述泊洛沙姆/交联羧甲基纤维素钠的制备方法为：将1g交联羧甲基纤维素钠和0.05g甘露醇升温至110～115℃保温混合10min，再加入1g泊洛沙姆和0.05g柠檬酸钠，继续在110～115℃保温混合15min，所得混合物转入-5～0℃环境中密封静置1h，最后利用超微粉碎机制成微粉，即得泊洛沙姆/交联羧甲基纤维素钠。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710335450.XA CN107137661A (zh) | 2017-05-12 | 2017-05-12 | 一种治疗疣状胃炎的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710335450.XA CN107137661A (zh) | 2017-05-12 | 2017-05-12 | 一种治疗疣状胃炎的中药组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107137661A true CN107137661A (zh) | 2017-09-08 |
Family
ID=59777295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710335450.XA Pending CN107137661A (zh) | 2017-05-12 | 2017-05-12 | 一种治疗疣状胃炎的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107137661A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732651A (zh) * | 2010-01-22 | 2010-06-16 | 姜晓红 | 一种治疗胃病的中药 |
-
2017
- 2017-05-12 CN CN201710335450.XA patent/CN107137661A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732651A (zh) * | 2010-01-22 | 2010-06-16 | 姜晓红 | 一种治疗胃病的中药 |
Non-Patent Citations (3)
| Title |
|---|
| 刘希霞: "自拟健胃消糜汤治疗慢性糜烂性胃炎74例疗效观察", 《天津中医药》 * |
| 李国安等: "牡贝消疣汤治疗疣状胃炎68例", 《四川中医》 * |
| 罗云玲: "疣状胃炎临证体会", 《云南中医学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006892A (zh) | 用于防治猪病毒性疾病的药物组合物、预混料及配合料 | |
| CN102670939B (zh) | 一种治疗家畜疥癣病的复方蜂胶组合物及其制备方法 | |
| CN103520616A (zh) | 一种治疗肾阴不足证型尿频的中药 | |
| CN105920268A (zh) | 治疗鸡坏死性肠炎的中药组合物及其制备方法 | |
| CN102640884B (zh) | 用于治疗猪气喘病的饲料及制备方法 | |
| CN107137661A (zh) | 一种治疗疣状胃炎的中药组合物 | |
| CN102727848B (zh) | 治疗家禽传染性法氏囊病的纯中药组合物及其制备方法 | |
| CN107970377A (zh) | 养心护心药香及其生产工艺 | |
| CN107137660A (zh) | 一种治疗乳腺增生的中药组合物 | |
| CN103083573A (zh) | 一种治疗酒精性脂肪肝的中药 | |
| CN102327412A (zh) | 一种用于治疗猪绦虫病的中药片剂及其制备方法 | |
| CN102670899B (zh) | 治疗牛羊肝片吸虫病的复方蜂胶组合物及其制备方法 | |
| CN102698204B (zh) | 一种治疗乳腺增生的壮药透皮贴剂及其制备方法 | |
| CN103432228A (zh) | 一种猪用止泻中药及制备方法 | |
| CN103990080A (zh) | 一种用于扁平疣的药物及其制备方法 | |
| CN107158138A (zh) | 一种治疗寻常型银屑病的外用中药组合物 | |
| CN102363025A (zh) | 一种治疗荨麻疹的中药配方 | |
| CN107929548A (zh) | 一种治疗溃疡性结肠炎的中药水泛丸及其制备方法和应用 | |
| US11224607B2 (en) | Anticancer composition of traditional Chinese medicine and preparation method thereof | |
| CN105902733A (zh) | 一种超声科具有抗甲状腺癌功效的制剂及制法 | |
| CN106620203A (zh) | 一种治疗牛蹄叶炎的中药组合物 | |
| CN106177391A (zh) | 一种治疗癌症的药物组合物及其制备方法 | |
| CN107158190A (zh) | 一种治疗子宫肌瘤伴出血的中药组合物 | |
| CN107115513A (zh) | 一种治疗子宫癌后期出血的中药组合物 | |
| CN102920860B (zh) | 治疗肝病的民族药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170908 |
|
| RJ01 | Rejection of invention patent application after publication |